InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.17
(
-0.25%
)
US TECH 100
19,257.60
(
-0.01%
)
Dow Jones
39,134.76
(
0.77%
)
Brent Oil
84.93
(
-0.09%
)
Bitcoin
63,830.69
(
-1.53%
)
Post# of 252279
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

JJM760

Send PM Follow Ignore
Followers 5
Posts 993
Boards Moderated 0
Alias Born 06/15/2010

JJM760

Re: DonShimoda post# 162298

Sunday, 06/09/2013 11:49:17 PM

Sunday, June 09, 2013 11:49:17 PM

Post# of 252279
Nice post from "The Don". I find this little nugget of particular interest:

"According to Ariad, 50% of crizotinib resistant patients progress with brain mets so this could end up being a key point of differentiation between the two drugs. It also may afford AP26113 a possible path to a first-line setting"

Could you expound a bit on that idea?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up